Theranexus announced the initial results of their Phase I/II clinical trial for juvenile Batten disease (CLN3). After a 9-week course of Batten-1 with the maximum dose of 600 mg/day, the first results of the Phase I/II trial enrolling six patients with juvenile Batten disease (CLN3) aged 17 and over showed good patient safety and tolerability, and a pharmacokinetic profile in line with expectations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.15 EUR | -0.43% | +1.77% | +2.68% |
Apr. 19 | Theranexus: share price rises following promising trial results | CF |
Mar. 11 | Theranexus: CEO takes over as Chairman of the Board | CF |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.68% | 9.6M | |
-3.18% | 102B | |
+1.28% | 96.29B | |
+2.13% | 22.18B | |
-15.73% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.53% | 16.36B | |
+4.64% | 13.97B | |
+32.33% | 12.17B |
- Stock Market
- Equities
- ALTHX Stock
- News Theranexus
- Theranexus Announces the Initial Results of Their Phase I/II Clinical Trial for Juvenile Batten Disease